Collaborations & Alliances

Confo Therapeutics, DyNAbind to Collaborate on Drug Discovery

Aims to identify novel small molecule GPCR-modulating compounds

Confo Therapeutics and DyNAbind GmbH entered a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR).   The collaboration will combine ConfoBody-enabled GPCRs with DyNAbind’s Dynamic DNA-encoded Library for the discovery of small molecule GPCR-modulating compounds. Under the terms of the agreement, Confo Therapeutics will gain exclusive, worldwide rights to any drug candidates arising from the collaboration and will be responsible for their development, manufacturing a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters